Fawzi Abu Rous, Thoracic Medical Oncologist at Henry Ford Health, shared a recent article on X:
“In this commentary, H. Jack West, Aliyah Pabani and I discuss the efficacy and safety of anti-angiogenesis agents in patients with squamous lung cancer.
With the growing experience and safety data with older agents such as Ramucirumab and newer bispecifics Ivonescimab, we believe it’s time to revise some of the outdated constraints on the use of these agents in patients with squamous non-small cell lung cancer at Lung Cancer Rx.”
Authors: Aliyah Pabani, Howard (Jack) West and Fawzi Abu Rous
For more updates, follow OncoDaily.